Breaking News, Collaborations & Alliances

AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing

Global CDMO’s Heidelberg facility supplies more pDNA material to help address growing needs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), is expanding its partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility. According to a recent news release from Pfizer and BioNTech, the companies have started to develop an Omicron-based COVID-19 vaccine with first batches expected to be ready for delivery by end of March 2022. “We are proud to continu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters